CN1799586B - Cold treating capsule and its preparation method - Google Patents
Cold treating capsule and its preparation method Download PDFInfo
- Publication number
- CN1799586B CN1799586B CN200510113103XA CN200510113103A CN1799586B CN 1799586 B CN1799586 B CN 1799586B CN 200510113103X A CN200510113103X A CN 200510113103XA CN 200510113103 A CN200510113103 A CN 200510113103A CN 1799586 B CN1799586 B CN 1799586B
- Authority
- CN
- China
- Prior art keywords
- cold
- cold relief
- capsule
- relief capsule
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a capsule for treating common cold and process for preparation, wherein the capsule is prepared from perilla leaf 20-36%, dandehon herb 8-23%, herba ecliptae 20-36%, plantain seeds 8-23% and shiny pricklyash 8-23% through grilling twice, filtering, concentrating and spray drying.
Description
Affiliated technical field
The invention belongs to technical field of traditional Chinese medicine pharmacy, relate to a kind of pure Chinese medicine cold relief capsule and preparation method thereof.
Background technology
Flu is common clinical, frequently-occurring disease, and clinical manifestation is symptoms such as heating, headache, sneeze, pharyngalgia, watery nasal discharge, cough.Folium Perillae is a monarch drug in this product cold relief capsule side, Folium Perillae: property and flavor of peppery and warm, return lung, spleen channel, and the fragrant property of loosing of the hot temperature of this product, external enwergy is led to space between skin and muscles, opens a mao key, delivers cold expelling, internal energy lung qi dispersing gas, the knot that reduces phlegm, sharp lung cough-relieving is held concurrently and can be led to space between skin and muscles.Compendium of Material Medica is called it, and " expelling pathogenic factors from muscles is delivered, dispersing wind and cold.Promoting the circulation of QI to alleviate the stagnation in middle-JIAO, the sharp lung of expectorant ".According to the cold and heat of exopathogen character, can distinguish hot temperature of compatibility or hot medicine of a cold nature flavor, this product focuses on inducing diaphoresis to expel pathogens, for diseases caused by exogenous pathogenic factor product commonly used, so be we's monarch drug.Herba Taraxaci, Herba Ecliptae are ministerial drug in the side.Herba Taraxaci: the property bitter but sweet flavor is cold, returns liver, stomach warp, and this product is cold in nature, heat-clearing and toxic substances removing, and the eliminating stagnation that expels the heat-evil with monarch drug Folium Perillae compatibility, makes it focus on suffering again and induces sweat, and is used for the card of affection due to external wind and heat.Herba Ecliptae: the sweet acid of nature and flavor is cold, returns liver, kidney channel.Clearing away heat and cooling blood plays the effect of heat-clearing and toxic substances removing jointly with Herba Taraxaci, so be ministerial drug altogether.Semen Plantaginis, Radix Zanthoxyli are adjuvant drug in the side.Semen Plantaginis, sweet in flavor and cold in property, return kidney, liver, lung meridian.Expelling wind and removing dampness, removing heat from the lung and dissipating phlegm, relieving cough and asthma.Be used for affection due to external wind and heat, impaired depurative descending of lung QI, phlegm-heat cough.More than two flavor assistants help the cough-relieving of monarch-minister drug removing heat from the lung and dissipating phlegm, so be adjuvant drug altogether.
Summary of the invention
The purpose of this invention is to provide a kind of treatment affection due to external wind and heat, the fever and aversion to wind due to the turbid phlegm obstructing in the lung, headache pharyngalgia, nasal obstruction watery nasal discharge, cold relief capsule of cough with copious phlegm and preparation method thereof.
For achieving the above object, a kind of cold relief capsule of the present invention is achieved through the following technical solutions:
1, the present invention is made by following component: (with heavily being weight percentage)
Folium Perillae 20%～36%, Herba Taraxaci 8%～23%, Herba Ecliptae 20%～36%, Semen Plantaginis 8%～23%, Radix Zanthoxyli 8%～23%.
Optimum weight proportioning of the present invention is: (percentage by weight)
Folium Perillae 28.55%, Herba Taraxaci 14.30%, Herba Ecliptae 28.55%, Semen Plantaginis 14.30, Radix Zanthoxyli 14.30%.
2, above-mentioned each component being made production method of the present invention is:
1. add for the first time the water of 14 times of amounts of medical material gross weight, decoct time decocting liquid of winning after 2 hours;
2. the water that adds for the second time 12 times of amounts of medical material gross weight decocts and gets decocting liquid for the second time after 1.5 hours;
3. the decocting liquid with secondary merges, filters, and filtrate is condensed into the clear paste that relative density is 1.15 (60 ℃);
4. with the clear paste spray drying, make granule, incapsulate, promptly.
The present invention is to be the pure Chinese medicine capsule of raw material with Folium Perillae, Herba Taraxaci, Herba Ecliptae, Semen Plantaginis, Radix Zanthoxyli, has clearing away heat and expelling pathogen in the exterior, the effect of preventing phlegm from forming and stopping coughing, be used for affection due to external wind and heat, fever and aversion to wind due to the turbid phlegm obstructing in the lung, headache pharyngalgia, nasal obstruction watery nasal discharge, cough with copious phlegm.
For showing the curative effect of medicine of the present invention,, benefit peace cold relief capsule has been carried out following relevant pharmacodynamics demonstration test with reference to the specification requirement of " study of tcm new drug guide " relevant such medicine pharmacodynamic study.
1 extracorporeal bacteria inhibitor test: adopt tube dilution method 5 common pathogenic bacterium of upper respiratory tract secondary infection to be carried out the mensuration of minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC).The result shows, this cold relief capsule all has in various degree antibacterial and bactericidal action to the common pathogen of upper respiratory tract infection,, secondly be beta hemolytic streptococcus [MIC/MBC:16.0/26.4 (extractum mg/mL)], bacillus pyocyaneus [MIC/MBC:20/20 (extractum mg/mL)], escherichia coli and streptococcus pneumoniae [MIC/MBC:40/40 (extractum mg/mL)] wherein to staphylococcus aureus the most responsive [MIC/MBC:4.8/4.8 (extractum mg/mL)].See table 1, table 2 for details.
This cold relief capsule of table 1 is to minimum inhibitory concentration (the inoculation bacterium amount: 10 of 5 kinds of common pathogens
5CFU/mL)
This cold relief capsule of table 2 is to minimum bactericidal concentration (the inoculation bacterium amount: 10 of 5 kinds of common pathogens
5CFU/mL)
2 separate heat test: adopt dry yeast to cause the rat fever model.If basic, normal, high three the dosage groups of model control group, aspirin positive drug control group (150mg/kg.bw) and this cold relief capsule (extractum 252,504 and 1008mg/kg.bw).Administration group gastric infusion every day once, successive administration 3 days; The 2.5h gastric infusion is once after pyrogenicity for positive drug control group; Model control group gives the equivalent distilled water.After the last administration immediately subcutaneous injection 10% dry yeast cause rat fever, repeat administration is once again for 2.5h after the pyrogenicity.Measuring the body temperature of 3h, 4h after the rat pyrogenicity, 5h, 6h, 7h, 8h respectively, is index with the body temperature changing value, observes the refrigeration function that is subjected to reagent.The result shows, dosage can obviously suppress the fervescence of 3h, 4h after the rat pyrogenicity in this cold relief capsule, and suppression ratio is respectively 51.0% and 36.3%, with model control group relatively, difference has significance meaning (P＜0.01 or 0.05); Be subjected to reagent high and low dose group each time point after pyrogenicity, not seeing has the trivial solution heat effect; Positive drug control group is each time point after pyrogenicity, all can obviously suppress rat temperature and raise, and its temperature approach and model control group compare, and difference all has significance meaning (P＜0.01).See table 3 for details.
This cold relief capsule of table 3 causes the influence of rat fever to dry yeast
Annotate: compare * P＜0.05, * * P＜0.01 (down together) with model control group.
Fig. 1 causes the influence of rat fever to dry yeast for this cold relief capsule
The scorching test of 3 caused by dimethylbenzene xylene: adopt mice caused by dimethylbenzene xylene auricle edema acute inflammation model.If basic, normal, high three the dosage groups of model control group, positive drug aspirin matched group (200mg/kg.bw) and this cold relief capsule (extractum 364,728 and 1456mg/kg.bw).Administration group gastric infusion every day once, successive administration 5 days; The positive drug control group gastric infusion once; Model control group gives the equivalent distilled water.1h causes inflammation after the last administration, causes scorching back 15 minutes with mice and takes off cervical vertebra execution.With the auricle swelling degree is index, observe be subjected to reagent to inflammation early stage ooze out, whether swelling have inhibitory action.The result shows: middle and high dosage of this cold relief capsule and positive drug xylol cause mice auricle swelling obvious inhibitory action, suppression ratio is respectively 15.3%, 24.7% and 34.6%, compare with model control group, difference has significance meaning (P＜0.01 or 0.05).
See table 4 for details.
This cold relief capsule of table 4 xylol causes the influence of mice auricle swelling
4 granuloma induced by implantation of cotton pellets test: adopt rat groin cotton balls implantation to set up the subacute inflammation model.If basic, normal, high three the dosage groups of model control group, positive drug hydrocortisone matched group (20mg/kg.bw) and this cold relief capsule (extractum 252,504 and 1008mg/kg.bw).Administration group each gastric infusion of every day at upper and lower noon once, positive drug control group gastric infusion every day once, successive administration 7 days, model control group gives the equivalent distilled water.Animal is put to death in the 1h dislocation after the last administration.With granuloma weight is index, observes to be subjected to reagent that the hypertrophy of inflammation later stage granulation tissue is had or not inhibitory action.The result shows: basic, normal, high three dosage of this cold relief capsule and positive drug all can obviously suppress the swollen formation of rat granuloma, suppression ratio is respectively 31.1%, 27.2%, 47.0% and 69.4%, compare with model control group, difference has significance meaning (P＜0.01 or 0.05).
See table 5 for details.
This cold relief capsule of table 5 is to the swollen influence that forms of rat granuloma
5 antitussives test: adopt citric acid to draw the method for coughing.The qualified Cavia porcellus of preliminary election (cough in 5 minutes number of times 〉=10 time) is divided into model control group at random, and positive drug carbetapentane citrate matched group (8mg/kg.bw) is subjected to basic, normal, high three the dosage groups of this cold relief capsule of reagent (extractum 217,434 and 868mg/kg.bw).The continuous gastric infusion of administration group 5 days, positive drug control group gastric infusion 3 days, model control group gives the equivalent distilled water.Behind the last administration 1h, Cavia porcellus is placed in the volumetrical exsiccator of 3L, draw with ultrasound atomizer spraying citric acid and cough (17.5%, 1min), be index with the cough number of times of Cavia porcellus in the 6min, observe the antitussive effect that is subjected to reagent.The result shows: basic, normal, high three dosage of this cold relief capsule and positive drug all can obviously reduce the cough number of times of Cavia porcellus, the cough-relieving rate is respectively 32.6%, 55.8%, 75.3% and 51.1%, compare with model control group, difference has significance meaning (P＜0.01).See table 6 for details.
This cold relief capsule of table 6 to the antitussive action of Cavia porcellus (X ± SD, n=11)
6 expectorant tests: adopt the phenol red method of mice.If basic, normal, high three the dosage groups of blank group, positive drug ammonium chloride matched group (100mg/kg.bw) and this cold relief capsule (crude drug 364,728 and 1456mg/kg.bw).Administration group gastric infusion every day once, successive administration 5 days; The positive drug control group gastric infusion once; The blank group gives the equivalent distilled water.30min after the last administration, the lumbar injection phenol red solution, animal is put to death in dislocation behind the 30min.Get one section of trachea, go into the phenol red amount of air flue intracavity with normal saline extraction by the respiratory mucus glandular secretion.With phenol red excretion amount is index, observes the phlegm-dispelling functions that is subjected to reagent.The result shows: middle and high two dosage of this cold relief capsule and positive drug all can make the phenol red excretion amount of mice trachea obviously increase, and increment rate is respectively 70.9%, 95.3% and 71.4%, compare with the blank group, and difference has significance meaning (P＜0.01).See table 7 for details.
This cold relief capsule of table 7 is to the excretory influence in mouse breathing road
7 analgesic test: adopt mouse writhing method.If basic, normal, high three the dosage groups of model control group, positive drug aspirin matched group (200mg/kg.bw) and this cold relief capsule (crude drug 364,728 and 1456mg/kg.bw).Administration group gastric infusion every day once, successive administration 5 days; Positive drug control group test gastric infusion on the same day once; Model control group gives the equivalent distilled water.1h after the last administration, lumbar injection acetic acid cause mice pain writhing response (male mice: 0.7%, 10mL/kg.bw, female mice: 0.8%, 12mL/kg.bw), be index with the body number of times of turning round of mice in the 15min, observe the analgesic activity that is subjected to reagent.The result shows: basic, normal, high three dosage of this cold relief capsule and positive drug all can obviously reduce acetic acid and cause mice pain writhing response number of times, suppression ratio is respectively 22.7%, 30.3%, 35.4% and 70.2%, compare with model control group, difference has significance meaning (P＜0.05 or 0.01).See table 8 for details.
This cold relief capsule of table 8 Dichlorodiphenyl Acetate causes the influence of mouse writhing reaction
Above-mentioned test shows that this cold relief capsule has the obvious in-vitro bacteriostasis to upper respiratory tract infection common pathogen (staphylococcus aureus and beta hemolytic streptococcus); Dry yeast is caused the rat fever fervescence certain inhibitory action is arranged; Inflammation due to the xylol is oozed out in early days with swelling obvious inhibitory action; Hypertrophy to inflammation later stage granulation tissue has obvious inhibitory action; Citric acid is caused the guinea pig cough obvious inhibitory action is arranged; It is phenol red obviously to strengthen the trachea excretion, promptly eliminates the phlegm by increasing the respiratory tract secretion; Dichlorodiphenyl Acetate causes mice pain writhing response obvious inhibitory action.
In sum, the inside and outside test of body shows that this cold relief capsule has significantly antibacterial, antiinflammatory, relieving cough and expelling phlegm, analgesic effect and certain refrigeration function.
Description of drawings
Below in conjunction with accompanying drawing cold relief capsule of the present invention is described in further detail.
Fig. 1 causes the figure that influences of rat fever to dry yeast for cold relief capsule of the present invention.
The specific embodiment
Embodiment
Take by weighing raw material (gram) by following proportioning:
Folium Perillae 833, Herba Taraxaci 417, Herba Ecliptae 833, Semen Plantaginis 417, Radix Zanthoxyli 417.
Production method is as follows:
The water that adds for the first time 14 times of amounts of medical material gross weight decocts time decocting liquid of winning after 2 hours; The water that adds for the second time 12 times of amounts of medical material gross weight decocts and gets decocting liquid for the second time after 1.5 hours; The decocting liquid of secondary is merged, filters, and filtrate is condensed into the clear paste that relative density is 1.15 (60 ℃), and spray drying is made granule, incapsulates, and promptly makes 1000 of cold relief capsules of the present invention.
Usage and consumption: oral, one time 4,3 times on the one.Have clearing away heat and expelling pathogen in the exterior, the effect of preventing phlegm from forming and stopping coughing is used for affection due to external wind and heat, the fever and aversion to wind due to the turbid phlegm obstructing in the lung, headache pharyngalgia, nasal obstruction watery nasal discharge, cough with copious phlegm.
Claims (3)
1. cold relief capsule, it is characterized in that: it is the medicament of being made by following raw material with weight percent meter:
Folium Perillae 20%～36%, Herba Taraxaci 8%～23%, Herba Ecliptae 20%～36%, Semen Plantaginis 8%～23%, Radix Zanthoxyli 8%～23%.
2. cold relief capsule according to claim 1, with weight percent meter wherein the weight proportion of each raw material be:
Folium Perillae 28.55%, Herba Taraxaci 14.30%, Herba Ecliptae 28.55%, Semen Plantaginis 14.30%, Radix Zanthoxyli 14.30%.
3. the preparation method of claim 1 or 2 described cold relief capsules is characterized in that:
1. add for the first time the water of 14 times of amounts of medical material gross weight, decoct time decocting liquid of winning after 2 hours;
2. the water that adds for the second time 12 times of amounts of medical material gross weight decocts and gets decocting liquid for the second time after 1.5 hours;
3. the decocting liquid with secondary merges, filters, and relative density was 1.15 clear paste when filtrate was condensed into 60 ℃;
4. with the clear paste spray drying, make granule, incapsulate, be i.e. cold relief capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510113103XA CN1799586B (en) | 2005-10-13 | 2005-10-13 | Cold treating capsule and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200510113103XA CN1799586B (en) | 2005-10-13 | 2005-10-13 | Cold treating capsule and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1799586A CN1799586A (en) | 2006-07-12 |
| CN1799586B true CN1799586B (en) | 2010-10-13 |
Family
ID=36809945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200510113103XA Active CN1799586B (en) | 2005-10-13 | 2005-10-13 | Cold treating capsule and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1799586B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102335417B (en) * | 2011-10-11 | 2013-02-27 | 宁波市江北威曼生物科技有限公司 | Health-care product for restoring physical strength in later period of cold |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1200296A (en) * | 1997-05-27 | 1998-12-02 | 泰安市社会福利院 | Spray for preventing and treating cold |
| CN1058632C (en) * | 1998-06-11 | 2000-11-22 | 叶莉莎 | Specific Chinese drug for curing common cold and abatement of fever |
| CN1365703A (en) * | 2001-01-15 | 2002-08-28 | 杨孟君 | Nano medicine for child to induce diaphoresis and its preparing process |
| CN1583073A (en) * | 2004-05-24 | 2005-02-23 | 谢国云 | Chinese patent medicinal prescription for catch-cold |
-
2005
- 2005-10-13 CN CN200510113103XA patent/CN1799586B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1200296A (en) * | 1997-05-27 | 1998-12-02 | 泰安市社会福利院 | Spray for preventing and treating cold |
| CN1058632C (en) * | 1998-06-11 | 2000-11-22 | 叶莉莎 | Specific Chinese drug for curing common cold and abatement of fever |
| CN1365703A (en) * | 2001-01-15 | 2002-08-28 | 杨孟君 | Nano medicine for child to induce diaphoresis and its preparing process |
| CN1583073A (en) * | 2004-05-24 | 2005-02-23 | 谢国云 | Chinese patent medicinal prescription for catch-cold |
Non-Patent Citations (5)
| Title |
|---|
| 曹汉麦.加味柴葛解肌汤治感冒体会.时珍国医国药10 6.1999,10(6),453. |
| 曹汉麦.加味柴葛解肌汤治感冒体会.时珍国医国药10 6.1999,10(6),453. * |
| 朱本浩.防感冒 用药茶.中国中医药报.2005,第007版 1-2. * |
| 郑新民.中医药防洽感冒研究进展.云南中医杂志 3.1987,(3),43-47. |
| 郑新民.中医药防洽感冒研究进展.云南中医杂志 3.1987,(3),43-47. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1799586A (en) | 2006-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657805B (en) | Loquat scented tea and preparation technology thereof | |
| CN101549060B (en) | Medicament containing gnetales for treating bronchitis and preparation method thereof | |
| CN101953985A (en) | Drug with function of removing heat from lung to relieve cough | |
| CN102302721A (en) | Pharmaceutical composition for treating bronchitis as well as preparation method and use thereof | |
| CN103721103B (en) | Medicine being used for the treatment of pig erysipelas and preparation method thereof | |
| CN101695327A (en) | Health-care kidney tea | |
| CN103182064A (en) | Medicine for treating cough due to wind-cold evil and preparation method thereof | |
| CN1939421A (en) | Antibacterial and antiviral Chinese medicinal composition | |
| CN102240353A (en) | Traditional Chinese drug anesthetic and preparation method thereof | |
| CN1799586B (en) | Cold treating capsule and its preparation method | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN101780211B (en) | Traditional Chinese medicine for treating infantile chronic cough and asthma | |
| CN103877384B (en) | A kind of Chinese medicine preparation and preparation method who treats the carcinoma of the rectum | |
| CN103719616B (en) | Feed for treating bloody flux of pigs and preparation method of feed | |
| CN103721095B (en) | Be used for preventing grippal Chinese medicine preparation | |
| CN1698814B (en) | Buccal tablet for treating chronic and acute pharyngitis and laryngitis and its preparation method | |
| CN104435441A (en) | Traditional Chinese medicine composition for treating diarrhea as well as preparation method and application | |
| CN101181500B (en) | Externally used medicament for curing respiratory system disease and preparation method thereof | |
| CN106562090A (en) | Feed for adult chickens | |
| CN105797007A (en) | Decoction medicine for treatment of pneumonia and preparation method thereof | |
| CN104189610A (en) | Traditional Chinese medicine composition for treating bronchitis | |
| CN104771629A (en) | Traditional Chinese medicine preparation used for treating pharyngitis | |
| CN104147094A (en) | Children's bronchitis syrup and preparation method thereof | |
| CN102961722B (en) | Traditional Chinese medicine composition for treating senile constipation | |
| CN1092975C (en) | Cough relieving oral medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |